ClinicalTrials.gg
WithdrawnNCT05661422Updated Mar 16, 2023

Analysis of Lung Sounds Collected by RESP Biosensor to Support Decision Making in Monitored Hospitalized Pediatric Patients

An observational study in Pediatric Respiratory Diseases, Asthma and RSV Infection, sponsored by Strados Labs, Inc.. Withdrawn at 1 site in United States. Open to participants aged 4 Years to 17 Years. Per ClinicalTrials.gov, last updated 2023-03-16.

Sponsored by Strados Labs, Inc. · Observational

How we know

Why this study was withdrawn
Sponsor Hold

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
0
Ages
4 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,696 studies in Asthma with a site in United States — 135 open to participants now, 189 under way, 19 of them phase 3. Asthma · United States.

Enrollment
316th of 330
0 · median 112
Started
2023
with 54 others
Observational
335 of 1,696
34 open now
Registered
1,507th of 1,696
by date

Among the 1,696 studies in Asthma with a site in United States, this one is the 316th largest by enrollment of the 330 observational ones that give a count, is one of 55 that started in 2023, is one of 335 observational ones, and was the 1,507th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

135 of the 1,696 studies in Asthma with a site in United States are open now. Recruiting first, the newest first:

130 more — sign in →

All 135 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 4 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,696 studies in Asthma with a site in United States, or all of them as a file.
02

Study summary

This observational clinical trial is designed to confirm whether RESP™ Biosensor could be deployed to support clinical decision making in challenging pediatric cases, minimize clinician-to-clinician variability in lung sound interpretation, obviate the need to disrupt change of shift or chart rounds with physicians, and create a durable archive of the patient's lung sounds for longitudinal comparison within or across hospitalizations.

03

Conditions studied

  • Pediatric Respiratory Diseases
  • Asthma
  • RSV Infection
  • COVID-19
04

Who can participate

Ages eligible
4 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

pediatric subjects who are admitted to the hospital with respiratory disease, including exacerbation of chronic respiratory disease and infection of RSV or COVID-19

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Children between the ages of 4 and 17 with documented physician-diagnosed respiratory disease including infection such as RSV or COVID
  2. Hospitalization projected for at least 24 hours after device placement
  3. Patient and parent/guardian able and willing to provide /assent.

Exclusion criteria

Exclusion Criteria:

  1. Patient and parent/guardian unable or unwilling to provide
  2. Patient expected to undergo prolonged invasive radiology procedure(s)
  3. Plan for discharge within 24 hours
  4. Patient expected to undergo major thoracic surgery
  5. History of adverse reaction or allergy to TegaDerm ® or similar product
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
0 participants (actual)
Patient registry
No

Groups and cohorts

  • Participants

    Device: RESP™ Biosensor

Interventions

  • DeviceRESP™ Biosensor

    The RESP Biosensor will be placed on the patient for periodic recording of auscultory sound.

    Also known as: RESP

06

What researchers measure

Primary outcomes

  1. Qualification and verification of lung sounds in pediatric population using RESP Biosensor

    Time frame: Periodic recording over 24 hours for inpatient stay

Secondary outcomes

  1. Acceptability and utilization of RESP Biosensor in clinicians, healthcare staff and patient families

    Time frame: Periodic recording over 24 hours for inpatient stay

  2. Limitations such as age in pediatric patients

    Time frame: Periodic recording over 24 hours for inpatient stay

07

Study locations

1 site
  • Memorial Health University Medical Center
    Savannah, Georgia 31404, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2023; primary completion for Dec 2023, 9 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2022
First posted
Dec 22, 2022
StartEst.
Mar 2023
Primary completionEst.
Dec 2023
CompletionEst.
Dec 2023
Last update
Mar 16, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05661422
Lead sponsor
Strados Labs, Inc.
Responsible party
Sponsor
First posted
Dec 22, 2022
Start date
Mar 2023 (estimated)
Primary completion
Dec 2023 (estimated)
Completion
Dec 2023 (estimated)
Last update
Mar 16, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion